

ASX ANNOUNCEMENT

29 February 2024

CORRECTION TO CLARITY PHARMACEUTICALS LIMITED 2023 ANNUAL REPORT

The Annual Report of Clarity Pharmaceuticals Limited ASX:CU6 (Company), published on 29 September 2023 on the Market Announcements Platform, included incorrect share-based payments values in the Remuneration Report on page 52 of the Annual Report. The table below includes the original incorrect disclosures together with the corrected values which are further explained below.

Historically the Company has assessed the probability of share-based payments vesting for KMP using historic staff turnover rates and these were not updated for actual amounts vested, resulting in an inadvertent understatement of the share-based payment expense and the KMP share based payment amounts disclosed. The KMP calculations have now been re-calculated and updated on an individual basis and the increase in the value (which is an 'expense' for accounting purposes) for KMP share based payment values reflect the higher likelihood of each individual KMP remaining with Clarity until the options have fully vested.

The impact of this correction on the disclosures in the 2023 Remuneration Report is as follows:

	Share-based Payments 2023		Share-based Payments 2022	
	Disclosed \$	Corrected \$	Disclosed \$	Corrected \$
KMP				
Non-Executive Directors				
Ms R Robinson	11,029	16,162	42,238	54,951
Dr C Roberts	11,029	16,162	42,238	54,951
Dr T Ramdahl	11,029	16,162	67,651	97,306
Dr C G O'Bryan-Tear	2,133	4,353	67,651	79,780
Executive Directors /Management				
Dr A Taylor	282,975	377,390	253,429	329,707
Dr C Biggin	250,318	341,291	318,529	438,207
Mr D Green	27,684	35,810	-	-

There are no other changes to the Annual Report as a result of this correction and the financial impact on the financial statements has been assessed as immaterial, being less than 2% of the loss for the period.

The company proposes to correct the comparatives in the 2024 Annual Report which will be released later this year.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR technology platform for the treatment of children and adults with cancer.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor

Executive Chairperson

ataylor@claritypharm.com

David Green

CFO

dgreen@claritypharm.com

This announcement has been authorised for release by the Executive Chairperson.